Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Apr 24;318(7191):1114-7.
doi: 10.1136/bmj.318.7191.1114.

Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study

A J Welton  1 , M R Vickers, J A Cooper, T W Meade, T M Marteau
Affiliations
Clinical Trial

Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study

A J Welton et al. BMJ. .

Abstract

Objective: To investigate whether including a placebo arm in a clinical trial of hormone replacement therapy influenced women's stated willingness to participate.

Design: Quasirandomised, interview based study.

Setting: 10 group practices in the Medical Research Council's General Practice Research Framework.

Participants: 436 postmenopausal women aged 45-64 who had not had a hysterectomy.

Main outcome measures: Stated willingness to enter a trial and reasons for the decisions made.

Results: Of 218 women told about the trial without a placebo arm, 85 (39%) indicated their willingness to enter compared with 65 (30%) of the 218 women told about the trial with the placebo arm (P=0.06). Part of this difference was due to explicit reluctance to take a placebo. Altruism and personal benefit were the reasons most frequently given for wanting to take part in a trial. The reasons most frequently cited for not wanting to take part were reluctance to restart periods, not wanting to take unknown or unnecessary tablets, or not wanting to interfere with present good health.

Conclusion: For preventive trials the inclusion of a placebo arm may reduce patients' willingness to participate.

PubMed Disclaimer

Figures

Figure
Figure
Flow chart of recruitment
See this image and copyright information in PMC

Comment in

References

    1. Henderson BE, Pike MC, Ross RK, Mack TM, Lobo RA. Re-evaluating the role of progestogen therapy after the menopause. Fert Steril. 1988;49:9–15S. - PubMed
    1. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1041. - PubMed
    1. Writing Group for the PEPI trial. Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1995;273:199–208. - PubMed
    1. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses’ health study. N Engl J Med. 1991;325:756–762. - PubMed
    1. Medical Research Council’s General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ. 1996;312:473–478. - PMC - PubMed

Publication types